Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies

Sorry, your subscription does not allow you to view this program.

IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer

Sorry, your subscription does not allow you to view this program.